• レポートコード:D005-11146 • 出版社/出版日:GlobalInfoResearch / 2020年5月28日 ※2024年版があります。お問い合わせください。 • レポート形態:英文、PDF、104ページ • 納品方法:Eメール • 産業分類:医療・製薬 |
Single User | ¥522,000 (USD3,480) | ▷ お問い合わせ |
Multi User | ¥783,000 (USD5,220) | ▷ お問い合わせ |
Corporate User | ¥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、神経遮断薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。神経遮断薬の種類別市場規模(ドロペリドール、ミダゾラム)、用途別市場規模(医療、科学研究、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報(販売量、市場シェア、製品概要、SWOT分析):Johnson & Johnso、Bristol-Myers Squibb、Pfizer、Eli Lilly、GlaxoSmithKline ・地域別グローバル市場分析 2015年-2020年 ・神経遮断薬の北米市場(アメリカ、カナダ、メキシコ) ・神経遮断薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア) ・神経遮断薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア) ・神経遮断薬の南米市場(ブラジル、アルゼンチン) ・神経遮断薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ) ・種類別分析:ドロペリドール、ミダゾラム ・用途別分析:医療、科学研究、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Neuroleptic market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Neuroleptic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Neuroleptic market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Neuroleptic market has been segmented into
Droperidol
Midazolam
By Application, Neuroleptic has been segmented into:
Medical Care
Scientific Research
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Neuroleptic market presented in the report. This section sheds light on the sales growth of different regional and country-level Neuroleptic markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Neuroleptic market.
The report offers in-depth assessment of the growth and other aspects of the Neuroleptic market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Neuroleptic Market Share Analysis
Neuroleptic competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Neuroleptic sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Neuroleptic sales, revenue and market share for each player covered in this report.
The major players covered in Neuroleptic are:
Johnson & Johnso
Bristol-Myers Squibb
Pfizer
Eli Lilly
GlaxoSmithKline
Among other players domestic and global, Neuroleptic market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Neuroleptic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Neuroleptic, with price, sales, revenue and global market share of Neuroleptic in 2018 and 2019.
Chapter 3, the Neuroleptic competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neuroleptic breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Neuroleptic market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Neuroleptic sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Neuroleptic Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Neuroleptic Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Droperidol
1.2.3 Midazolam
1.3 Market Analysis by Application
1.3.1 Overview: Global Neuroleptic Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Medical Care
1.3.3 Scientific Research
1.3.4 Others
1.4 Overview of Global Neuroleptic Market
1.4.1 Global Neuroleptic Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Johnson & Johnso
2.1.1 Johnson & Johnso Details
2.1.2 Johnson & Johnso Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Johnson & Johnso SWOT Analysis
2.1.4 Johnson & Johnso Product and Services
2.1.5 Johnson & Johnso Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bristol-Myers Squibb SWOT Analysis
2.2.4 Bristol-Myers Squibb Product and Services
2.2.5 Bristol-Myers Squibb Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Pfizer SWOT Analysis
2.3.4 Pfizer Product and Services
2.3.5 Pfizer Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 GlaxoSmithKline
2.5.1 GlaxoSmithKline Details
2.5.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 GlaxoSmithKline SWOT Analysis
2.5.4 GlaxoSmithKline Product and Services
2.5.5 GlaxoSmithKline Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Neuroleptic Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Neuroleptic Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Neuroleptic Manufacturer Market Share in 2019
3.3.2 Top 6 Neuroleptic Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Neuroleptic Sales, Revenue and Market Share by Regions
4.1.1 Global Neuroleptic Sales and Market Share by Regions (2015-2020)
4.1.2 Global Neuroleptic Revenue and Market Share by Regions (2015-2020)
4.2 North America Neuroleptic Sales and Growth Rate (2015-2020)
4.3 Europe Neuroleptic Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Neuroleptic Sales and Growth Rate (2015-2020)
4.5 South America Neuroleptic Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Neuroleptic Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Neuroleptic Sales, Revenue and Market Share by Country
5.1.1 North America Neuroleptic Sales and Market Share by Country (2015-2020)
5.1.2 North America Neuroleptic Revenue and Market Share by Country (2015-2020)
5.2 United States Neuroleptic Sales and Growth Rate (2015-2020)
5.3 Canada Neuroleptic Sales and Growth Rate (2015-2020)
5.4 Mexico Neuroleptic Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Neuroleptic Sales, Revenue and Market Share by Country
6.1.1 Europe Neuroleptic Sales and Market Share by Country (2015-2020)
6.1.2 Europe Neuroleptic Revenue and Market Share by Country (2015-2020)
6.2 Germany Neuroleptic Sales and Growth Rate (2015-2020)
6.3 UK Neuroleptic Sales and Growth Rate (2015-2020)
6.4 France Neuroleptic Sales and Growth Rate (2015-2020)
6.5 Russia Neuroleptic Sales and Growth Rate (2015-2020)
6.6 Italy Neuroleptic Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Neuroleptic Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Neuroleptic Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Neuroleptic Revenue and Market Share by Regions (2015-2020)
7.2 China Neuroleptic Sales and Growth Rate (2015-2020)
7.3 Japan Neuroleptic Sales and Growth Rate (2015-2020)
7.4 Korea Neuroleptic Sales and Growth Rate (2015-2020)
7.5 India Neuroleptic Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Neuroleptic Sales and Growth Rate (2015-2020)
7.7 Australia Neuroleptic Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Neuroleptic Sales, Revenue and Market Share by Country
8.1.1 South America Neuroleptic Sales and Market Share by Country (2015-2020)
8.1.2 South America Neuroleptic Revenue and Market Share by Country (2015-2020)
8.2 Brazil Neuroleptic Sales and Growth Rate (2015-2020)
8.3 Argentina Neuroleptic Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Neuroleptic Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Neuroleptic Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Neuroleptic Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Neuroleptic Sales and Growth Rate (2015-2020)
9.3 Turkey Neuroleptic Sales and Growth Rate (2015-2020)
9.4 Egypt Neuroleptic Sales and Growth Rate (2015-2020)
9.5 South Africa Neuroleptic Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Neuroleptic Sales and Market Share by Type (2015-2020)
10.2 Global Neuroleptic Revenue and Market Share by Type (2015-2020)
10.3 Global Neuroleptic Price by Type (2015-2020)
11 Global Neuroleptic Market Segment by Application
11.1 Global Neuroleptic Sales Market Share by Application (2015-2020)
11.2 Global Neuroleptic Revenue Market Share by Application (2015-2020)
11.3 Global Neuroleptic Price by Application (2015-2020)
12 Market Forecast
12.1 Global Neuroleptic Sales, Revenue and Growth Rate (2021-2025)
12.2 Neuroleptic Market Forecast by Regions (2021-2025)
12.2.1 North America Neuroleptic Market Forecast (2021-2025)
12.2.2 Europe Neuroleptic Market Forecast (2021-2025)
12.2.3 Asia-Pacific Neuroleptic Market Forecast (2021-2025)
12.2.4 South America Neuroleptic Market Forecast (2021-2025)
12.2.5 Middle East & Africa Neuroleptic Market Forecast (2021-2025)
12.3 Neuroleptic Market Forecast by Type (2021-2025)
12.3.1 Global Neuroleptic Sales Forecast by Type (2021-2025)
12.3.2 Global Neuroleptic Market Share Forecast by Type (2021-2025)
12.4 Neuroleptic Market Forecast by Application (2021-2025)
12.4.1 Global Neuroleptic Sales Forecast by Application (2021-2025)
12.4.2 Global Neuroleptic Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Neuroleptic Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Neuroleptic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Neuroleptic Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Johnson & Johnso Basic Information, Manufacturing Base and Competitors
Table 8. Johnson & Johnso Neuroleptic Major Business
Table 9. Johnson & Johnso Neuroleptic Total Revenue (USD Million) (2018-2019)
Table 10. Johnson & Johnso SWOT Analysis
Table 11. Johnson & Johnso Neuroleptic Product and Services
Table 12. Johnson & Johnso Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 14. Bristol-Myers Squibb Neuroleptic Major Business
Table 15. Bristol-Myers Squibb Neuroleptic Total Revenue (USD Million) (2018-2019)
Table 16. Bristol-Myers Squibb SWOT Analysis
Table 17. Bristol-Myers Squibb Neuroleptic Product and Services
Table 18. Bristol-Myers Squibb Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Neuroleptic Major Business
Table 21. Pfizer Neuroleptic Total Revenue (USD Million) (2018-2019)
Table 22. Pfizer SWOT Analysis
Table 23. Pfizer Neuroleptic Product and Services
Table 24. Pfizer Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 26. Eli Lilly Neuroleptic Major Business
Table 27. Eli Lilly Neuroleptic Total Revenue (USD Million) (2018-2019)
Table 28. Eli Lilly SWOT Analysis
Table 29. Eli Lilly Neuroleptic Product and Services
Table 30. Eli Lilly Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 32. GlaxoSmithKline Neuroleptic Major Business
Table 33. GlaxoSmithKline Neuroleptic Total Revenue (USD Million) (2018-2019)
Table 34. GlaxoSmithKline SWOT Analysis
Table 35. GlaxoSmithKline Neuroleptic Product and Services
Table 36. GlaxoSmithKline Neuroleptic Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Global Neuroleptic Sales by Manufacturer (2018-2019) (K MT)
Table 38. Global Neuroleptic Revenue by Manufacturer (2018-2019) (USD Million)
Table 39. Global Neuroleptic Sales by Regions (2015-2020) (K MT)
Table 40. Global Neuroleptic Sales Market Share by Regions (2015-2020)
Table 41. Global Neuroleptic Revenue by Regions (2015-2020) (USD Million)
Table 42. North America Neuroleptic Sales by Countries (2015-2020) (K MT)
Table 43. North America Neuroleptic Sales Market Share by Countries (2015-2020)
Table 44. North America Neuroleptic Revenue by Countries (2015-2020) (USD Million)
Table 45. North America Neuroleptic Revenue Market Share by Countries (2015-2020)
Table 46. Europe Neuroleptic Sales by Countries (2015-2020) (K MT)
Table 47. Europe Neuroleptic Sales Market Share by Countries (2015-2020)
Table 48. Europe Neuroleptic Revenue by Countries (2015-2020) (USD Million)
Table 49. Asia-Pacific Neuroleptic Sales by Regions (2015-2020) (K MT)
Table 50. Asia-Pacific Neuroleptic Sales Market Share by Regions (2015-2020)
Table 51. Asia-Pacific Neuroleptic Revenue by Regions (2015-2020) (USD Million)
Table 52. South America Neuroleptic Sales by Countries (2015-2020) (K MT)
Table 53. South America Neuroleptic Sales Market Share by Countries (2015-2020)
Table 54. South America Neuroleptic Revenue by Countries (2015-2020) (USD Million)
Table 55. South America Neuroleptic Revenue Market Share by Countries (2015-2020)
Table 56. Middle East & Africa Neuroleptic Sales by Countries (2015-2020) (K MT)
Table 57. Middle East & Africa Neuroleptic Sales Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Neuroleptic Revenue by Countries (2015-2020) (USD Million)
Table 59. Middle East & Africa Neuroleptic Revenue Market Share by Countries (2015-2020)
Table 60. Global Neuroleptic Sales by Type (2015-2020) (K MT)
Table 61. Global Neuroleptic Sales Share by Type (2015-2020)
Table 62. Global Neuroleptic Revenue by Type (2015-2020) (USD Million)
Table 63. Global Neuroleptic Revenue Share by Type (2015-2020)
Table 64. Global Neuroleptic Sales by Application (2015-2020) (K MT)
Table 65. Global Neuroleptic Sales Share by Application (2015-2020)
Table 66. Global Neuroleptic Sales Forecast by Regions (2021-2025) (K MT)
Table 67. Global Neuroleptic Market Share Forecast by Regions (2021-2025)
Table 68. Global Neuroleptic Sales Forecast by Type (2021-2025) (K MT)
Table 69. Global Neuroleptic Market Share Forecast by Type (2021-2025)
Table 70. Global Neuroleptic Sales Forecast by Application (2021-2025)
Table 71. Global Neuroleptic Market Share Forecast by Application (2021-2025)
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Neuroleptic Picture
Figure 2. Global Sales Market Share of Neuroleptic by Type in 2019
Figure 3. Droperidol Picture
Figure 4. Midazolam Picture
Figure 5. Neuroleptic Sales Market Share by Application in 2018
Figure 6. Medical Care Picture
Figure 7. Scientific Research Picture
Figure 8. Others Picture
Figure 9. Global Neuroleptic Market Status and Outlook (2015-2025) (USD Million)
Figure 10. United States Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 11. Canada Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 12. Mexico Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 13. Germany Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 14. France Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 15. UK Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Russia Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Italy Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 18. China Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 19. Japan Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 20. Korea Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 21. India Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Southeast Asia Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 23. Australia Neuroleptic Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 24. Brazil Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Egypt Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 26. Saudi Arabia Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 27. South Africa Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Turkey Neuroleptic Revenue (Value) and Growth Rate (2015-2025)
Figure 29. Global Neuroleptic Sales Market Share by Manufacturer in 2019
Figure 30. Global Neuroleptic Revenue Market Share by Manufacturer in 2019
Figure 31. Top 3 Neuroleptic Manufacturer (Revenue) Market Share in 2019
Figure 32. Top 6 Neuroleptic Manufacturer (Revenue) Market Share in 2019
Figure 33. Key Manufacturer Market Share Trend
Figure 34. Global Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 35. Global Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 36. Global Neuroleptic Revenue Market Share by Regions (2015-2020)
Figure 37. Global Neuroleptic Revenue Market Share by Regions in 2018
Figure 38. North America Neuroleptic Sales and Growth Rate (2015-2020)
Figure 39. Europe Neuroleptic Sales and Growth Rate (2015-2020)
Figure 40. Asia-Pacific Neuroleptic Sales and Growth Rate (2015-2020)
Figure 41. South America Neuroleptic Sales and Growth Rate (2015-2020)
Figure 42. Middle East & Africa Neuroleptic Sales and Growth Rate (2015-2020)
Figure 43. North America Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 44. North America Neuroleptic Sales Market Share by Countries (2015-2020)
Figure 45. North America Neuroleptic Sales Market Share by Countries in 2018
Figure 46. North America Neuroleptic Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 47. North America Neuroleptic Revenue Market Share by Countries in 2018
Figure 48. United States Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 49. Canada Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 50. Mexico Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 51. Europe Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 52. Europe Neuroleptic Revenue Market Share by Countries (2015-2020)
Figure 53. Europe Neuroleptic Revenue Market Share by Countries in 2019
Figure 54. Germany Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 55. UK Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 56. France Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 57. Russia Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 58. Italy Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 59. Asia-Pacific Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 60. Asia-Pacific Neuroleptic Sales Market Share by Regions 2019
Figure 61. Asia-Pacific Neuroleptic Revenue Market Share by Regions 2019
Figure 62. China Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 63. Japan Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 64. Korea Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 65. India Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 66. Southeast Asia Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 67. South America Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 68. South America Neuroleptic Sales Market Share by Countries in 2019
Figure 69. South America Neuroleptic Revenue Market Share by Countries in 2019
Figure 70. Brazil Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 71. Argentina Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 72. Middle East and Africa Neuroleptic Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. Middle East and Africa Neuroleptic Sales Market Share by Countries in 2019
Figure 74. Middle East and Africa Neuroleptic Revenue Market Share by Countries (2015-2020)
Figure 75. Middle East and Africa Neuroleptic Revenue Market Share by Countries in 2019
Figure 76. Saudi Arabia Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 77. Egypt Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 78. Turkey Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 79. South Africa Neuroleptic Sales and Growth Rate (2015-2020) (K MT)
Figure 80. Global Neuroleptic Sales and Growth Rate (2021-2025) (K MT)
Figure 81. Global Neuroleptic Revenue and Growth Rate (2021-2025) (USD Million)
Figure 82. North America Sales Neuroleptic Market Forecast (2021-2025) (K MT)
Figure 83. Europe Sales Neuroleptic Market Forecast (2021-2025) (K MT)
Figure 84. Asia-Pacific Sales Neuroleptic Market Forecast (2021-2025) (K MT)
Figure 85. South America Sales Neuroleptic Market Forecast (2021-2025) (K MT)
Figure 86. Middle East & Africa Sales Neuroleptic Market Forecast (2021-2025) (K MT)
Figure 87. Sales Channel: Direct Channel vs Indirect Channel